Next Investors logo grey

ImpediMed receives order for 16 SOZO units to address lymphoedema


Published 01-APR-2020 09:28 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), has received the first order of 16 units under the recently announced national purchasing agreement with a US oncology care network for its SOZO® Digital Health Platform and Lymphoedema Prevention Program.

This is a significant development for the group, and while it is currently in a trading halt and this news will not be reflected in movements in its share price today, the company could receive support on Friday when it is due to recommence trading.

Based on the depth of buyers currently in the queue to buy stock when the company recommences trading there could be a significant rerating.

The initial order of 16 SOZO units will establish a comprehensive Lymphoedema Prevention Program in key centres from this nationally recognised oncology care network.

In commenting on the significance for the group in terms of national distribution, chief executive Richard Carreon said, “We believe these centres will develop the model from which we will jointly expand our program nationally.”

IPD pic

95% reduction in lymphoedema progression at one year.

The national purchasing agreement, which was announced on 23 March, allows 1,200 physicians at 470 cancer treatment locations across the US access to SOZO and ImpediMed’s BIS (L-Dex®) lymphoedema assessment.

Together, these physicians treat over 1 million patients annually.

The Lymphoedema Prevention Program utilises ImpediMed's Test, Trigger, TreatTM protocol for early detection and intervention of cancer-related lymphoedema.

Routine lymphoedema testing of cancer survivors uses the company's SOZO device with BIS (LDex) technology.

sozo revenue

A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention.

ImpediMed's PREVENT Trial, the largest multi-site, randomised controlled trial ever performed to study lymphoedema prevention, showed that this protocol resulted in a 95% reduction in lymphoedema progression at one year.

Currently, one in three at-risk cancer survivors will develop secondary lymphoedema related to their cancer treatment, costing the US healthcare system approximately $7 billion every year.

The aim of the Lymphoedema Prevention Program is to help educate healthcare providers and patients that with the proper protocols in place, lymphoedema can be detected and managed before it becomes a debilitating chronic condition.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.